Pharmaceutical Executive Daily
New research suggests Ozempic may reduce biological age.
The FDA has approved Bayer's Lynkuet for menopausal hot flashes.
Novartis has a $12 billion merger agreement to acquire Avidity Biosciences.
- Lynkuet, also known as elinzanetant, is the first dual neurokinin 1 and 3 receptor antagonist.
- It treats moderate to severe vasomotor symptoms associated with menopause.
- Lynkuet provides a non-hormonal option for patients seeking relief from menopausal symptoms.
New research suggesting Ozempic may reduce biological age.
Author's summary: New pharmaceutical developments and approvals.